Skip to content

Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders

Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders (Insula-TOP)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03277339
Acronym
Insula-TOP
Enrollment
52
Registered
2017-09-11
Start date
2017-01-19
Completion date
2020-02-05
Last updated
2022-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxious Disorders

Keywords

Generalized anxious disorders, Thermal cure, paroxetine

Brief summary

Multicenter study comparing paroxetine (n=30) versus thermal cure (n=30) in patients with a diagnosis of Generalised Anxiety Disorders

Detailed description

Multicenter study comparing paroxetine (n=30) versus thermal cure (n=30) in patients with a diagnosis of Generalised Anxiety Disorders Main objective is to quantify the therapeutic benefit of a thermal cure on generalized anxiety disorders and to understand the psycho-biological substrates of this improvement. Secondary objectives: * A decrease of Insula activity at rest during the answers to aversive pictures and during the task of subjective measurement of heartbeat. * A decrease of sensibility to emotional interference by subliminal presentation of emotional words thanks to a lexical task and a color recognition task associated to simultaneous measurement of physiological indicator of emotional activity ( dermal resistance)

Interventions

DRUGParoxetine

Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.

Thermal cure is realized for 3 weeks

Sponsors

Association Francaise pour la Recherche Thermale
CollaboratorOTHER
Les thermes de Saujon
CollaboratorUNKNOWN
Poitiers University Hospital
CollaboratorOTHER
Centre National de la Recherche Scientifique (CeRCA, umr 7295), France
CollaboratorUNKNOWN
Centre Hospitalier Henri Laborit
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnostic of generalized anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) * No treatment by antidepressant for at least 2 months * No treatment by anxiolytic/neuroleptic/bete blockers/antipsychotic for at least 3 weeks * Global score of Hamilton Anxiety Scale (HAM-A) is greater or equal to 20 * Score of HAM-A symptoms greater or equal to 8 * Score of Hamilton Depressive Scale (HAM-D) lower or equal to 7 * Age: Participants will be males and females, 18-75 years of age included. * For women, no ongoing pregnancy/ negative pregnancy test * No wounds * Affiliation to a social security system (recipient or assignee) * Signed written inform consent form

Exclusion criteria

* Treatment by antidepressant for at least 2 months or a treatment by anxiolytic, neuroleptic for at least 3 weeks * Psychotropic treatment (antidepressant, anxiolytic and neuroleptic) between the preinclusion and inclusion * Psychotherapy during the 3 months prior to the inclusion * Thermal cure during the 6 months prior to the inclusion * Treatment by paroxetine for at least 1 month with dose equal or superior to 20 mg per day during the 12 months prior to the inclusion * Contraindication to paroxetine * Enhanced protection (minors, pregnancies women, nursing women,people deprived of liberty by administrative or judicial decision, ...) * Blood donation during the 3 months prior to the inclusion

Design outcomes

Primary

MeasureTime frame
Decrease Insula activity during a resting state taskThe evaluation of primary end point is performed between day 1 and day 24

Secondary

MeasureTime frame
Sensibility non conscientious to emotional interference in lexical task and in color identification taskD= Day D1/D24/D56
Modulation of electrodermal response during presentation of predictive stimuli on aversive images and its links to the subjective view of emotional stateD= Day D24
Modulation of electrodermal response during presentation of predictive stimuli on aversive images and insula activationD= Day D24
Changes of HAM-A score between day 1 and day 24.The evaluation of primary end point is performed between day 1 and day 24
Evolution (Day 1 and Day 24) of the correlation between HAM-A global score and 1- the measure of heartbeat 2- emotional reactivity during aversive images task.D= Day D1/D24.
Difference (Day 1 and Day 24) of correlations between the symptoms severity and the activation of insula cortex during 1-aversive images task, 2-heartbeat measure task.D= Day D1/D24.
Evaluation of efficacy of the thermal cure Day 56 using HAM-A scoreD= Day D56
Lost of significant correlation (Day 24) between HAM-A score, introspective acuity and insula hyperactivationD= Day D24

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026